Reuters -- U.S. regulators have asked for more information on dosing proposed for a drug from Novartis AG for “smoker’s lung”, or chronic obstructive pulmonary disease, the Swiss group said on Monday.
Reuters -- U.S. regulators have asked for more information on dosing proposed for a drug from Novartis AG for “smoker’s lung”, or chronic obstructive pulmonary disease, the Swiss group said on Monday.
